TNF-α polymorphisms in juvenile idiopathic arthritis: Which potential clinical implications?

International Journal of Rheumatology

Volumn 2012, Issue , 2012, Pages

  Scardapane, A ^a   Breda, L ^a   Lucantoni, M ^a   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ARTHRITIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HETEROZYGOSITY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PATHOGENESIS; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PSORIATIC ARTHRITIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EID: 84869054804     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2012/756291     Document Type: Review

References (142)

1. Helmick C. G., Felson D. T., Lawrence R. C., Gabriel S., Hirsch R., Kwoh C. K., Liang M. H., Kremers H. M., Mayes M. D., Merkel P. A., Pillemer S. R., Reveille J. D., Stone J. H., Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis and Rheumatism 2008 58 1 15 25 2-s2.0-38149138096 10.1002/art.23177
2. Martini A., Lovell D. J., Juvenile idiopathic arthritis: state of the art and future perspectives. Annals of the Rheumatic Diseases 2010 69 7 1260 1263 2-s2.0-77954976614 10.1136/ard.2010.133033
3. Murray K., Thompson S. D., Glass D. N., Pathogenesis of juvenile chronic arthritis: genetic and environmental factors. Archives of Disease in Childhood 1997 77 6 530 534 2-s2.0-0031443280 (Pubitemid 28016378)
4. Ravelli A., Martini A., Juvenile idiopathic arthritis. The Lancet 2007 369 9563 767 778 2-s2.0-33847287323 10.1016/S0140-6736(07)60363-8
5. Donn R. P., Barrett J. H., Farhan A., Stopford A., Pepper L., Shelley E., Davies N., Ollier W. E. R., Thomson W., Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. Arthritis and Rheumatism 2001 44 4 802 810 2-s2.0-0035050125 10.1002/1529-0131(200104)44:4802::AID- ANR136>3.0.CO;2-G (Pubitemid 32319772)
6. Smith A. J. P., Humphries S. E., Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine and Growth Factor Reviews 2009 20 1 43 59 2-s2.0-60949088752 10.1016/j.cytogfr.2008.11.006
7. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M. F., Oksenberg J., McNicholl J., Pociot F., Hardt C., D'Alfonso S., Cytokine gene polymorphism in human disease: on-line databases. Genes and Immunity 1999 1 1 3 19 2-s2.0-0033188361 (Pubitemid 129622776)
8. Lepore L., Pennesi M., Saletta S., Perticarari S., Presani G., Prodan M., Study of IL-2, IL-6, TNF α IFN γ and β in the serum and synovial fluid of patients with juvenile chronic arthritis. Clinical and Experimental Rheumatology 1994 12 5 561 565 2-s2.0-0028138864 (Pubitemid 24323903)
9. Mangge H., Kenzian H., Gallistl S., Neuwirth G., Liebmann P., Kaulfersch W., Beaufort F., Muntean W., Schauenstein K., Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis and Rheumatism 1995 38 2 211 220 2-s2.0-0028816371 10.1002/art.1780380209
10. Kutukculer N., Caglayan S., Aydogdu F., Study of pro-inflammatory (TNF- α IL-1 α IL-6) and T-cell-derived (IL- 2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clinical Rheumatology 1998 17 4 288 292 2-s2.0-0031694535 10.1007/BF01451007 (Pubitemid 28417039)
11. Field M., Tumour necrosis factor polymorphisms in rheumatic diseases. QJM 2001 94 5 237 246 2-s2.0-0034997576 (Pubitemid 32492745)
12. Hajeer A. H., Hutchinson I. V., TNF- α gene polymorphism: clinical and biological implications. Microscopy Research and Technique 2000 50 3 216 228 2-s2.0-0034254552 10.1002/1097-0029(20000801)50:3216::AID-JEMT5>3.0.CO;2-Q (Pubitemid 30610098)
13. Zeggini E., Thomson W., Kwiatkowski D., Richardson A., Ollier W., Donn R., Abinun M., Becker M., Bell A., Craft A., Crawley E., David J., Foster H., Gardener-Medwin J., Griffin J., Hall A., Hall M., Herrick A., Hollingworth P., Holt L., Jones S., Pountain G., Ryder C., Southwood T., Stewart I., Woo P., Wyatt S., Venning H., Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis and Rheumatism 2002 46 12 3304 3311 2-s2.0-0036901071 10.1002/art.10698 (Pubitemid 35453541)
14. Schmeling H., Wagner U., Peterson A., Horneff G., Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2006 24 1 103 108 2-s2.0-33645086646
15. Brinkman B. M. N., Huizinga T. W. J., Kurban S. S., Van Der Velde E. A., Schreuder G. M. T., Hazes J. M. W., Breedveld F. C., Verweij C. L., Tumour necrosis factor α gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? British Journal of Rheumatology 1997 36 5 516 521 2-s2.0-0030810790
16. Low A. S., Gonzalez-Gay M. A., Akil M., Amos R. S., Bax D. E., Cannings C., Hajeer A., Till S. H., Winfield J., Ollier W. E., Wilson A. G., TNF+489 polymorphism does not contribute to susceptibility to rheumatoid arthritis. Clinical and Experimental Rheumatology 2002 20 6 829 832 2-s2.0-1842856987 (Pubitemid 35446974)
17. Hayward K., Wallace C. A., Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Research and Therapy 2009 11 1, article 216 2-s2.0-69249203713 10.1186/ar2619
18. Lovell D. J., Giannini E. H., Reiff A., Jones O. Y., Schneider R., Olson J. C., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A., Lange M., Finck B. K., Burge D. J., Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and Rheumatism 2003 48 1 218 226 2-s2.0-0037231476 10.1002/art.10710 (Pubitemid 36091666)
19. Verweij C. L., Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Annals of the Rheumatic Diseases 1999 58 supplement 1 I20 I26 2-s2.0-0032731689
20. Maxwel J. R., Potter C., Hyrich K. L., Barton A., Worthington J., Isaacs J. D., Morgan A. W., Wilson A. G., Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics 2008 17 22 3532 3538 2-s2.0-54949146894 10.1093/hmg/ddn245
21. Liu C., Batliwalla F., Li W., Lee A., Roubenoff R., Beckman E., Khalili H., Damle A., Kern M., Furie R., Dupuis J., Plenge R. M., Coenen M. J. H., Behrens T. W., Carulli J. P., Gregersen P. K., Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Molecular Medicine 2008 14 9-10 575 581 2-s2.0-55049089081 10.2119/2008-00056.Liu
22. Gambhir D., Lawrence A., Aggarwal A., Misra R., Mandal S. K., Naik S., Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. Rheumatology International 2010 30 9 1211 1217 2-s2.0-77953717195 10.1007/s00296-009-1131-0
23. Miterski B., Drynda S., Böschow G., Klein W., Oppermann J., Kekow J., Epplen J. T., Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genetics 2004 5, article 2 2-s2.0-2442697764 10.1186/1471-2156-5-2 (Pubitemid 38671570)
24. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A. M., Suarez-Almazor M. E., Woo P., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. Journal of Rheumatology 2004 31 2 390 392 2-s2.0-10744230484 (Pubitemid 38160763)
25. Lawrence R. C., Helmick C. G., Arnett F. C., Deyo R. A., Felson D. T., Giannini E. H., Heyse S. P., Hirsch R., Hochberg M. C., Hunder G. G., Liang M. H., Pillemer S. R., Steen V. D., Wolfe F., Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998 41 5 778 799 2-s2.0-0031968825 10.1002/1529-0131(199805)41: 5778::AID-ART4>3.0.CO;2-V (Pubitemid 28225778)
26. Prahalad S., Glass D. N., A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatric Rheumatology 2008 6, article 11 2-s2.0-49749135691 10.1186/1546-0096-6-11
27. Ozen S., Tucker L. B., Miller L. C., Identification of Th subsets in juvenile rheumatoid arthritis confirmed by intracellular cytokine staining. Journal of Rheumatology 1998 25 8 1651 1653 2-s2.0-0031928796 (Pubitemid 28364780)
28. Gattorno M., Facchetti P., Ghiotto F., Vignola S., Buoncompagni A., Prigione I., Picco P., Pistoia V., Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype. Clinical and Experimental Immunology 1997 109 1 4 11 2-s2.0-0030825456 (Pubitemid 27293876)
29. Prahalad S., Genetic analysis of juvenile rheumatoid arthritis: approaches to complex traits. Current Problems in Pediatric and Adolescent Health Care 2006 36 3 83 90 2-s2.0-32144451134 10.1016/j.cppeds.2005.10.009 (Pubitemid 43205292)
30. Thomson W., Donn R., Juvenile idiopathic arthritis genetics-What's new? What's next? Arthritis Research 2002 4 5 302 306 2-s2.0-0036024682 10.1186/ar591 (Pubitemid 34947144)
31. Ploski R., Vinje O., Ronningen K. S., Spurkland A., Sorskaar D., Vartdal F., Forre O., HLA class II alleles and heterogeneity of juvenile rheumatoid arthritis: DRB10101 may define a novel subset of the disease. Arthritis and Rheumatism 1993 36 4 465 472 2-s2.0-0027406912 (Pubitemid 23104033)
32. Date Y., Seki N., Kamizono S., Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5 ′ -flanking region of the TNF α gene and HLA genes. Arthritis and Rheumatism 1999 42 12 2577 2582 2-s2.0-0033512202 10.1002/1529-0131(199912)42:122577::AID-ANR10>3.0. CO;2-O (Pubitemid 30327174)
33. Woo P., Colbert R. A., An overview of genetics of paediatric rheumatic diseases. Best Practice and Research 2009 23 5 589 597 2-s2.0-72049106398 10.1016/j.berh.2009.08.001
34. Moroldo M. B., Donnelly P., Saunders J., Glass D. N., Giannini E. H., Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis. Arthritis and Rheumatism 1998 41 9 1620 1624 2-s2.0-0031658698 10.1002/1529-0131(199809)41: 91620::AID-ART12>3.0.CO;2-L (Pubitemid 28459920)
35. Oen K., Malleson P. N., Cabral D. A., Rosenberg A. M., Petty R. E., Nickerson P., Reed M., Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology 2005 44 9 1115 1121 2-s2.0-24144480556 10.1093/rheumatology/keh689 (Pubitemid 41236017)
36. Mourão A. F., Caetano-Lopes J., Costa P., Canhão H., Santos M. J., Pinto P., Brito I., Nicola P., Cavaleiro J., Teles J., Sousa A., Gomes J. M., Branco J., Da Costa J. T., Pedro J. G., De Queiroz M. V., Fonseca J. E., Tumor necrosis factor- α -308 genotypes influence inflammatory activity and TNF- α serum concentrations in children with juvenile idiopathic arthritis. Journal of Rheumatology 2009 36 4 837 842 2-s2.0-66149150972 10.3899/jrheum.080615
37. Elahi M. M., Asotra K., Matata B. M., Mastana S. S., Tumor necrosis factor alpha308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochimica et Biophysica Acta 2009 1792 3 163 172 2-s2.0-61349179432 10.1016/j.bbadis.2009.01.007
38. Aguillón J. C., Escobar A., Ferreira V., Aguirre A., Ferreira L., Molina M. C., Ferreira A., Daily production of human tumor necrosis factor in LPS-stimulated ex vivo blood culture assays. European Cytokine Network 2001 12 1 105 110 2-s2.0-0035066993 (Pubitemid 32281196)
39. Kollias G., Douni E., Kassiotis G., Kontoyiannis D., The function of tumour necrosis factor and receptors in models of multi- organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Annals of the Rheumatic Diseases 1999 58 supplement 1 I32 I39 2-s2.0-0032704934
40. Bradley J. R., TNF-mediated inflammatory disease. Journal of Pathology 2008 214 2 149 160 2-s2.0-38549102077 10.1002/path.2287 (Pubitemid 351160153)
41. Barbara J. A. J., Van Ostade X., Lopez A. F., Tumour necrosis factor-alpha (TNF- α): the good, the bad and potentially very effective. Immunology and Cell Biology 1996 74 5 434 443 2-s2.0-0029830209 (Pubitemid 26342128)
42. Aguillón J. C., Cruzat A., Aravena O., Salazar L., Llanos C., Cuchacovich M., Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 2006 211 1-2 75 84 2-s2.0-31444456793 10.1016/j.imbio.2005.09.005 (Pubitemid 43150109)
43. Jiménez-Morales S., Velázquez-Cruz R., Ramírez-Bello J., Bonilla-González E., Romero-Hidalgo S., Escamilla-Guerrero G., Cuevas F., Espinosa-Rosales F., Martínez-Aguilar N. E., Gómez-Vera J., Baca V., Orozco L., Tumor necrosis factor- α is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Human Immunology 2009 70 4 251 256 2-s2.0-63149096066 10.1016/j.humimm.2009.01.027
44. Jacob C. O., Hwang F., Lewis G. D., Stall A. M., Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine 1991 3 6 551 561 2-s2.0-0026246529
45. Bouma G., Crusius J. B. A., Oudkerk Pool M., Kolkman J. J., Von Blomberg B. M. E., Kostense P. J., Giphart M. J., Schreuder G. M. T., Meuwissen S. G. M., Peña A. S., Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scandinavian Journal of Immunology 1996 43 4 456 463 2-s2.0-9244244710 (Pubitemid 26104933)
46. Tartaglia L. A., Weber R. F., Figari I. S., Reynolds C., Palladino M. A., Goeddel D. V., The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proceedings of the National Academy of Sciences of the United States of America 1991 88 20 9292 9296 2-s2.0-0026072837 (Pubitemid 21915617)
47. McDermott M. F., Autosomal dominant recurrent fevers. Clinical and genetic aspects. Revue du Rhumatisme 1999 66 10 484 491 2-s2.0-0032710431 (Pubitemid 29500795)
48. Spriggs D. R., Deutsch S., Kufe D. W., Genomic structure, induction, and production of TNF-alpha. Immunology series 1992 56 3 34 2-s2.0-0026461349
49. Warlé M. C., Farhan A., Metselaar H. J., Hop W. C. J., Perrey C., Zondervan P. E., Kap M., Kwekkeboom J., Ijzermans J. N. M., Tilanus H. W., Pravica V., Hutchinson I. V., Bouma G. J., Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transplantation 2003 9 2 170 181 2-s2.0-12244278306 10.1053/jlts.2002.50014 (Pubitemid 36204567)
50. Wilson A. G., Symons J. A., Mcdowell T. L., Mcdevitt H. O., Duff G. W., Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 1997 94 7 3195 3199 2-s2.0-0030954180 10.1073/pnas.94.7.3195 (Pubitemid 27157287)
51. Bayley J. P., Ottenhoff T. H. M., Verweij C. L., Is there a future for TNF promoter polymorphisms? Genes and Immunity 2004 5 5 315 329 2-s2.0-4344579064 10.1038/sj.gene.6364055 (Pubitemid 39139757)
52. Mira J. P., Cariou A., Grall F., Delclaux C., Losser M. R., Heshmati F., Cheval C., Monchi M., Teboul J. L., Riché F., Leleu G., Arbibe L., Mignon A., Delpech M., Dhainaut J. F., Association of TNF2, a TNF- α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999 282 6 561 568 2-s2.0-0033546610 10.1001/jama.282.6.561 (Pubitemid 29380293)
53. Bayley J. P., De Rooij H., Van Den Elsen P. J., Huizinga T. W. J., Verweij C. L., Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF- α promoter. Cytokine 2001 14 6 316 323 2-s2.0-0035927489 10.1006/cyto.2001.0902 (Pubitemid 32730472)
54. Brinkman B. M. N., Zuijdgeest D., Kaijzel E. L., Breedveld F. C., Verweij C. L., Relevance of the tumor necrosis factor alpha (TNF α) -308 promoter polymorphism in TNF α gene regulation. Journal of Inflammation 1996 46 1 32 41 2-s2.0-0029966034 (Pubitemid 26090860)
55. Kroeger K. M., Carville K. S., Abraham L. J., The -308 tumor necrosis factor- α promoter polymorphism effects transcription. Molecular Immunology 1997 34 5 391 399 2-s2.0-0030862033 10.1016/S0161-5890(97)00052-7 (Pubitemid 27368335)
56. Abraham L. J., Kroeger K. M., Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. Journal of Leukocyte Biology 1999 66 4 562 566 2-s2.0-0032881603 (Pubitemid 29489880)
57. Kaijzel E. L., Bayley J. P., Van Krugten M. V., Smith L., Van De Linde P., Bakker A. M., Breedveld F. C., Huizinga T. W. J., Verweij C. L., Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes and Immunity 2001 2 3 135 144 2-s2.0-0035348006 10.1038/sj.gene.6363747 (Pubitemid 33674878)
58. Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-Lafontaine N., Roland S., Mahieu P., Malaise M., De Groote D., Louis R., Belaiche J., Tumour necrosis factor (TNF) gene polymorphism influences TNF- α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clinical and Experimental Immunology 1998 113 3 401 406 2-s2.0-7344251714 10.1046/j.1365-2249.1998.00662.x (Pubitemid 28410565)
59. Huizinga T. W. J., Westendorp R. G. J., Bollen E. L. E. M., Keijsers V., Brinkman B. M. N., Langermans J. A. M., Breedveld F. C., Verweij C. L., Van Gaer L. D., Dams L., Crusius J. B. A., García-Gonzalez A., Van Oosten B. W., Polman C. H., Peña A. S., TNF- α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. Journal of Neuroimmunology 1997 72 2 149 153 2-s2.0-0031047430 10.1016/S0165-5728(96)00182-8 (Pubitemid 27062770)
60. Kubota T., McNamara D. M., Wang J. J., Trost M., McTiernan C. F., Mann D. L., Feldman A. M., Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation 1998 97 25 2499 2501 2-s2.0-0032581020 (Pubitemid 28294494)
61. Fong C. L. W., Siddiqui A. H., Mark D. F., Identification and characterization of a novel repressor site in the human tumor necrosis factor α gene. Nucleic Acids Research 1994 22 6 1108 1114 2-s2.0-0028318464
62. Pociot F., D'Alfonso S., Compasso S., Scorza R., Richiardi P. M., Functional analysis of a new polymorphism in the human TNF α gene promoter. Scandinavian Journal of Immunology 1995 42 4 501 504 2-s2.0-0028805395 10.1111/j.1365-3083.1995.tb03686.x
63. Ozen S., Alikasifoglu M., Bakkaloglu A., Duzova A., Jarosova K., Nemcova D., Besbas N., Vencovsky J., Tuncbilek E., Tumour necrosis factor α G → A -238 and G → A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatology 2002 41 2 223 227 2-s2.0-0036101612 (Pubitemid 34537902)
64. Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J., Chimeric anti-TNF- α monoclonal antibody cA2 binds recombinant transmembrane TNF- α and activates immune effector functions. Cytokine 1995 7 3 251 259 2-s2.0-0029004771 10.1006/cyto.1995.0029
65. Knight J. C., Udalova I., Hill A. V. S., Greenwood B. M., Peshu N., Marsh K., Kwiatkowski D., A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nature Genetics 1999 22 2 145 150 2-s2.0-0032993434 10.1038/9649 (Pubitemid 29264807)
66. Knight J. C., Keating B. J., Rockett K. A., Kwiatkowski D. P., In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nature Genetics 2003 33 4 469 475 2-s2.0-0037381011 10.1038/ng1124 (Pubitemid 36390008)
67. Butler D. M., Maini R. N., Feldmann M., Brennan F. M., Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF- α antibody with the interleukin-1 receptor antagonist. European Cytokine Network 1995 6 4 225 230 2-s2.0-0029617952 (Pubitemid 26018294)
68. Feldmann M., Brennan F. M., Maini R. N., Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 1996 14 397 440 2-s2.0-0029876121 10.1146/annurev.immunol.14.1.397 (Pubitemid 26130190)
69. Cuenca J., Cuchacovich M., Pérez C., Ferreira L., Aquirre A., Schiattino I., Soto L., Cruzat A., Salazar-Onfray F., Aguillón J. C., The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology 2003 42 2 308 313 2-s2.0-0345700858 10.1093/rheumatology/keg092 (Pubitemid 36305619)
70. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. The EMBO Journal 1991 10 13 4025 4031 2-s2.0-0026039673 (Pubitemid 21905432)
71. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J., Woody J. N., Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis and Rheumatism 1993 36 12 1681 1690 2-s2.0-0027438710 10.1002/art.1780361206 (Pubitemid 23360007)
72. Kempeni J., Preliminary results of early clinical trials with the fully human anti- TNF α monoclonal antibody D2E7. Annals of the Rheumatic Diseases 1999 58 supplement 1 I70 I72 2-s2.0-0032705008
73. Weinblatt M. E., The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999 38 2 19 23 2-s2.0-0032692512 10.1093/rheumatology/38.suppl1.19 (Pubitemid 29533268)
74. Modesto C., Patiño-García A., Sotillo-Piñeiro E., Merino J., García-Consuegra J., Merino R., Rua M. J., Sierrasesúmaga L., Arnal C., TNF- α promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. Scandinavian Journal of Rheumatology 2005 34 6 451 454 2-s2.0-30344459396 10.1080/03009740510026652 (Pubitemid 43062200)
75. Hohler T., Kruger A., Schneider P. M., Schopf R. E., Knop J., Rittner C., Meyer zum Buschenfelde K.-H., Marker-Hermann E., A TNF- α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. Journal of Investigative Dermatology 1997 109 4 562 565 2-s2.0-0030766567 (Pubitemid 27433602)
76. Martínez A., Fernández-Arquero M., Pascual-Salcedo D., Conejero L., Alves H., Balsa A., De La Concha E. G., Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis and Rheumatism 2000 43 6 1366 1370 2-s2.0-0342732899 10.1002/1529-0131(200006)43:61366::AID-ANR21>3.0.CO;2-S (Pubitemid 30416323)
77. Khanna D., Wu H., Park G., Gersuk V., Gold R. H., Nepom G. T., Wong W. K., Sharp J. T., Reed E. F., Paulus H. E., Tsao B. P., Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis and Rheumatism 2006 54 4 1105 1116 2-s2.0-33646345082 10.1002/art.21750 (Pubitemid 43672923)
78. Fonseca J. E., Cavaleiro J., Teles J., Sousa E., Andreozzi V. L., Antunes M., Amaral-Turkman M. A., Canhão H., Mourão A. F., Lopes J., Caetano-Lopes J., Weinmann P., Sobral M., Nero P., Saavedra M. J., Malcata A., Cruz M., Melo R., Braña A., Miranda L., Patto J. V., Barcelos A., da Silva J. C., Santos L. M., Figueiredo G., Rodrigues M., Jesus H., Quintal A., Carvalho T., da Silva J. A. P., Branco J., Queiroz M. V., Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Research and Therapy 2007 9, article R37 2-s2.0-34247855059 10.1186/ar2173 (Pubitemid 46696553)
79. Popa O. M., Bojinca M., Bojinca V., Dutescu M. I., Meirosu M., Caisan R. E., Ciofu C., Bara C., Popa L. O., A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population. International Journal of Molecular Sciences 2011 12 8 5052 5059 2-s2.0-80052158793 10.3390/ijms12085052
80. Giardina E., Hüffmeier U., Ravindran J., Behrens F., Lepre T., McHugh N. J., Korendowych E., Burkhardt H., Novelli G., Reis A., Tumor necrosis factor promoter polymorphism TNF -857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis and Rheumatism 2011 63 12 3801 3806 2-s2.0-82455210508 10.1002/art.30591
81. Van Krugten M. V., Huizinga T. W. J., Kaijzel E. L., Zanelli E., Drossaers-Bakker K. W., Van De Linde P., Hazes J. M. W., Zwinderman A. H., Breedveld F. C., Verweij C. L., Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes and Immunity 1999 1 2 91 96 2-s2.0-0033224478 (Pubitemid 129627285)
82. Kooloos W. M., Wessels J. A. M., Van Der Kooij S. M., Allaart C. F., Huizinga T. W. J., Guchelaar H. J., Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond. Annals of the Rheumatic Diseases 2009 68 8, article 1371 2-s2.0-67651225612 10.1136/ard.2008.096891
83. Plant D., Bowes J., Potter C., Hyrich K. L., Morgan A. W., Wilson A. G., Isaacs J. D., Barton A., Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis and Rheumatism 2011 63 3 645 653 2-s2.0-79952442211 10.1002/art.30130
84. Breda L., Del Torto M., De Sanctis S., Chiarelli F., Biologics in children's autoimmune disorders: efficacy and safety. European Journal of Pediatrics 2011 170 2 157 167 2-s2.0-78951491339 10.1007/s00431-010-1238-z
85. Padyukov L., Lampa J., Heimbürger M., Ernestam S., Cederholm T., Lundkvist I., Andersson P., Hermansson Y., Harju A., Klareskog L., Bratt J., Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 2003 62 6 526 529 2-s2.0-0038823966 10.1136/ard.62.6.526 (Pubitemid 36606284)
86. Schmeling H., Horneff G., Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatology International 2007 27 4 383 386 2-s2.0-33846285755 10.1007/s00296-006-0208-2 (Pubitemid 46122283)
87. Cimaz R., Cazalis M. A., Reynaud C., Gerloni V., Zulian F., Biggioggero M., Martini G., Pontikaki I., Fantini F., Mougin B., Miossec P., IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Annals of the Rheumatic Diseases 2007 66 7 900 904 2-s2.0-34347209025 10.1136/ard.2006.067454 (Pubitemid 46999790)
88. Basic J., Pavlovic D., Jevtovic-Stoimenov T., Vojinovic J., Susic G., Stojanovic I., Kocic G., Milosevic V., Cvetkovic T., Marinkovic M., Veljkovic A., Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF- α -308GG genotype. Journal of Physiology and Biochemistry 2010 66 2 173 180 2-s2.0-77955095454 10.1007/s13105-010-0022-x
89. Ongaro A., De Mattei M., Pellati A., Caruso A., Ferretti S., Masieri F. F., Fotinidi M., Farina I., Trotta F., Padovan M., Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNF α therapy in rheumatoid arthritis? Rheumatology International 2008 28 9 901 908 2-s2.0-49949152271 10.1007/s00296-008-0552-5
90. Guis S., Balandraud N., Bouvenot J., Auger I., Toussirot E., Wendling D., Mattel J. P., Nogueira L., Mugnier B., Legeron P., Landt O., Serre G., Roudier J., Roudier C., Influence of -308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis. Arthritis Care & Research 2007 57 8 1426 1430 2-s2.0-37349093406 10.1002/art.23092 (Pubitemid 350308840)
91. Seitz M., Wirthmüller U., Möller B., Villiger P. M., The -308 tumour necrosis factor- α gene polymorphism predicts therapeutic response to TNF α -blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007 46 1 93 96 2-s2.0-33845595254 10.1093/rheumatology/kel175 (Pubitemid 44932793)
92. O'Rielly D. D., Roslin N. M., Beyene J., Pope A., Rahman P., TNF- α 308 G/A polymorphism and responsiveness to TNF- α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics Journal 2009 9 3 161 167 2-s2.0-67349101771 10.1038/tpj.2009.7
93. Kang C. P., Lee K. W., Yoo D. H., Kang C., Bae S. C., The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005 44 4 547 552 2-s2.0-18744365197 10.1093/rheumatology/keh550 (Pubitemid 41511149)
94. Mugnier B., Roudier J., Martinez A., Salido M., Fernandez-Arquero M., De La Concha E. G., Fernández-Gutiérrez B., Tumor necrosis factor α haplotypes versus tumor necrosis factor α -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis. Arthritis and Rheumatism 2004 50 12 4075 4077 2-s2.0-10444289768 10.1002/art.20801 (Pubitemid 39643961)
95. Balog A., Klausz G., Gál J., Molnár T., Nagy F., Ocsovszky I., Gyulai Z., Mándi Y., Investigation of the prognostic value of TNF- α gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF- α production and apoptosis. Pathobiology 2004 71 5 274 280 2-s2.0-5644233733 10.1159/000080062 (Pubitemid 39370363)
96. Fonseca J. E., Carvalho T., Cruz M., Nero P., Sobral M., Mourão A. F., Cavaleiro J., Ligeiro D., Abreu I., Carmo-Fonseca M., Branco J. C., Polymorphism at position -308 of the tumour factor α gene and rheumatoid arthritis pharmacogenetics. Annals of the Rheumatic Diseases 2005 64 5 793 794 2-s2.0-20244363493 10.1136/ard.2004.028167 (Pubitemid 40559320)
97. Lee Y. H., Ji J. D., Bae S. C., Song G. G., Associations between tumor necrosis factor- α (TNF- α) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF- α blockers in rheumatoid arthritis: a metaanalysis update. Journal of Rheumatology 2010 37 4 740 746 2-s2.0-77950632641 10.3899/jrheum.090707
98. Chatzikyriakidou A., Georgiou I., Voulgari P. V., Venetsanopoulou A. I., Drosos A. A., Combined tumour necrosis factor- α and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF- α therapy and explain controversies of studies based on a single polymorphism. Rheumatology 2007 46 6 1034 1035 2-s2.0-34447296681 10.1093/rheumatology/kem041 (Pubitemid 47062517)
99. Pinto J. A., Rego I., Fernandez-López C., Freire M., Fernandez-Sueiro J. L., Blanco F. J., Rodríguez-Gomez M., Sanmarti R., Cañete J. D., Polymorphisms in genes encoding tumor necrosis factor- α and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. Journal of Rheumatology 2008 35 1 177 178 2-s2.0-38149118006
100. Pavy S., Toonen E. J. M., Miceli-Richard C., Barrera P., Van Riel P. L. C. M., Criswell L. A., Mariette X., Coenen M. J. H., Tumour necrosis factor α -308G→A polymorphism is not associated with response to TNF α blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Annals of the Rheumatic Diseases 2010 69 6 1022 1028 2-s2.0-77953701245 10.1136/ard.2009.117622
101. Suarez-Gestal M., Perez-Pampin E., Calaza M., Gomez-Reino J. J., Gonzalez A., Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Research and Therapy 2010 12 2, article R72 2-s2.0-77951240136 10.1186/ar2990
102. Marotte H., Arnaud B., Diasparra J., Zrioual S., Miossec P., Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor. Arthritis and Rheumatism 2008 58 5 1258 1263 2-s2.0-43949122575 10.1002/art.23430 (Pubitemid 351705914)
103. Miceli-Richard C., Comets E., Verstuyft C., Tamouza R., Loiseau P., Ravaud P., Kupper H., Becquemont L., Charron D., Mariette X., A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 4 478 484 2-s2.0-41849134745 10.1136/ard.2007.074104 (Pubitemid 351498427)
104. Diak P., Siegel J., La Grenade L., Choi L., Lemery S., McMahon A., Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis and Rheumatism 2010 62 8 2517 2524 2-s2.0-77955371398 10.1002/art.27511
105. Horneff G., Foeldvari I., Minden K., Moebius D., Hospach T., Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 2011 50 1 230 236 2-s2.0-79951691845 10.1093/rheumatology/keq361
106. Horneff G., Hospach T., Dannecker G., Föll D., Haas J. P., Girschick H. J., Huppertz H. I., Keitzer R., Laws H. J., Michels H., Minden K., Trauzeddel R., Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009. Zeitschrift fur Rheumatologie 2010 69 6 561 567 2-s2.0-77956344683 10.1007/s00393-009-0600-x
107. McCroskery P., Wallace C. A., Lovell D. J., Stryker S., Chernyukhin N., Blosch C., Zack D. J., Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatric Rheumatology 2010 8, article 18 2-s2.0-77953340599 10.1186/1546-0096-8-18
108. Harrison M., Nordstom B., Gu Y., Mercaldi C., Aquino P., Mines D., Risk of malignancy in biologics-naive juvenile arthritis patients. Annals of the Rheumatic Diseases 2010 3, article 631
109. Simard J. F., Neovius M., Hagelberg S., Askling J., Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Annals of the Rheumatic Diseases 2010 3, article 81
110. Beukelman T., Xie F., Chen L., Baddley J. W., Delzell E., Grijalva C. G., Lewis J. D., Ouellet-Hellstrom R., Patkar N. M., Saag K. G., Winthrop K. L., Curtis J. R., Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis and Rheumatism 2012 64 8 2773 2780 2-s2.0-84864420538 10.1002/art.34458
111. Nordstrom B. L., Mines D., Gu Y., Mercaldi C., Aquino P., Harrison M. J., Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologics. Arthritis Care & Research. In press
112. Wolfe F., Michaud K., Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis and Rheumatism 2004 50 6 1740 1751 2-s2.0-2642554059 10.1002/art.20311 (Pubitemid 38725085)
113. Wolfe F., Michaud K., The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis and Rheumatism 2007 56 5 1433 1439 2-s2.0-34248547187 10.1002/art.22579 (Pubitemid 46764070)
114. Leombruno J. P., Einarson T. R., Keystone E. C., The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Annals of the Rheumatic Diseases 2009 68 7 1136 1145 2-s2.0-67549117204 10.1136/ard.2008. 091025
115. Dommasch E., Gelfand J. M., Is there truly a risk of lymphoma from biologic therapies? Dermatologic Therapy 2009 22 5 418 430 2-s2.0-69749086912 10.1111/j.1529-8019.2009.01258.x
116. Pallavicini F. B., Caporali R., Sarzi-Puttini P., Atzeni F., Bazzani C., Gorla R., Marchesoni A., Favalli E. G., Montecucco C., Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmunity Reviews 2010 9 3 175 180 2-s2.0-72449154112 10.1016/j.autrev.2009. 07.006
117. Franklin J., Lunt M., Bunn D., Symmons D., Silman A., Incidence of lymphoma in a large primary care derived cohort or cases of inflammatory polyarthritis. Annals of the Rheumatic Diseases 2006 65 5 617 622 2-s2.0-33646240605 10.1136/ard.2005.044784
118. Cron R. Q., Beukelman T., Guilt by associationwhat is the true risk of malignancy in children treated with etanercept for JIA? Pediatric Rheumatology 2010 8, article 23 2-s2.0-77955541285 10.1186/1546-0096-8-23
119. Raaschou P., Simard J. F., Neovius M., Askling J., Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis?: a national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis and Rheumatism 2011 63 7 1812 1822 2-s2.0-79959833640 10.1002/art.30247
120. Balkwill F., Tumor necrosis factor or tumor promoting factor? Cytokine and Growth Factor Reviews 2002 13 2 135 141 2-s2.0-0036005888 10.1016/S1359-6101(01)00020-X (Pubitemid 34229388)
121. Ferrajoli A., Keating M. J., Manshouri T., Giles F. J., Dey A., Estrov Z., Koller C. A., Kurzrock R., Thomas D. A., Faderl S., Lerner S., O'Brien S., Albitar M., The clinical significance of tumor necrosis factor- α plasma level in patients having chronic lymphocytic leukemia. Blood 2002 100 4 1215 1219 2-s2.0-0037103258 (Pubitemid 34864274)
122. Liu R. Y., Fan C., Liu G., Olashaw N. E., Zuckerman K. S., Activation of p38 mitogen activated protein is required for tumor Necrosis factor- α -supported proliferation of leukemia and lymphoma cell lines. The Journal of Biological Chemistry 2000 275 28 21086 21095 2-s2.0-0034647525 10.1074/jbc.M001281200 (Pubitemid 30481800)
123. Jaiswal M., LaRusso N. F., Burgart L. J., Gores G. J., Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Research 2000 60 1 184 190 2-s2.0-0033969322 (Pubitemid 30058750)
124. Nabors L. B., Suswam E., Huang Y., Yang X., Johnson M. J., King P. H., Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Research 2003 63 14 4181 4187 2-s2.0-0042674150 (Pubitemid 36917944)
125. Polunovsky V. A., Wendt C. H., Ingbar D. H., Peterson M. S., Bitterman P. B., Induction of endothelial cell apoptosis by TNF α: modulation by inhibitors of protein synthesis. Experimental Cell Research 1994 214 2 584 594 2-s2.0-0027971199 10.1006/excr.1994.1296 (Pubitemid 24310817)
126. Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C., Dual role of tumor necrosis factor- α in angiogenesis. American Journal of Pathology 1992 140 3 539 544 2-s2.0-0026568694
127. Manusama E. R., Nooijen P. T. G. A., Stavast J., Durante N. M. C., Marquet R. L., Eggermont A. M. M., Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. British Journal of Surgery 1996 83 4 551 555 2-s2.0-0029985727 10.1002/bjs.1800830438 (Pubitemid 26120788)
128. Seynhaeve A. L. B., De Wilt J. H. W., Van Tiel S. T., Eggermont A. M. M., Ten Hagen T. L. M., Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. British Journal of Cancer 2002 86 7 1174 1179 2-s2.0-0037041644 (Pubitemid 34438093)
129. Marsh H. P., Haldar N. A., Bunce M., Marshall S. E., Le Monier K., Winsey S. L., Christodoulos K., Cranston D., Welsh K. I., Harris A. L., Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. British Journal of Cancer 2003 89 6 1096 1101 2-s2.0-0141990968 10.1038/sj.bjc.6601165 (Pubitemid 37239218)
130. Nakajima K., Sasaki M., Nojima D., Oh B. R., Ishii N., Miura K., Dahiya R., Tumor necrosis factor- α gene mutations and genotype changes in renal cell carcinoma. Journal of Urology 2001 165 2 612 615 2-s2.0-0035181626 10.1097/00005392-200102000-00082 (Pubitemid 32060488)
131. Oh B. R., Sasaki M., Perinchery G., Ryu S. B., Park Y. I., Carroll P., Dahiya R., Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor- α (TNF- α) gene in patients with prostate cancer. Journal of Urology 2000 163 5 1584 1587 2-s2.0-0034048288 (Pubitemid 30226331)
132. Tsukasaki K., Miller C. W., Kubota T., Takeuchi S., Fujimoto T., Ikeda S., Tomonaga M., Philip Koeffler H., Tumor necrosis factor α polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Research 2001 61 9 3770 3774 2-s2.0-0035328524 (Pubitemid 32694991)
133. Mestiri S., Bouaouina N., Ahmed S. B., Khedhaier A., Jrad B. B., Remadi S., Chouchane L., Genetic variation in the tumor necrosis factor- α promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001 91 4 672 678 2-s2.0-0035864931 10.1002/1097-0142(20010215)91:4672::AID-CNCR1050>3.0.CO;2-J (Pubitemid 32173290)
134. Jeng J. E., Tsai J. F., Chuang L. Y., Ho M. S., Lin Z. Y., Hsieh M. Y., Chen S. C., Chuang W. L., Wang L. Y., Yu M. L., Dai C. Y., Chang J. G., Tumor necrosis factor- α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007 9 11 987 992 2-s2.0-36049033413 10.1593/neo.07781 (Pubitemid 350089911)
135. Machado J. C., Figueiredo C., Canedo P., Pharoah P., Carvalho R., Nabais S., Castro Alves C., Campos M. L., Van Doorn L. J., Caldas C., Seruca R., Carneiro F., Sobrinho-Simões M., A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003 125 2 364 371 2-s2.0-0042667008 10.1016/S0016-5085(03) 00899-0 (Pubitemid 36929416)
136. Ho S. Y., Wang Y. J., Chen H. L., Chen C. H., Chang C. J., Wang P. J., Chen H. H. W., Guo H. R., Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor- α promoter gene. Cancer Causes and Control 2004 15 7 657 663 2-s2.0-4043102715 10.1023/B:CACO.0000036173.99930.75 (Pubitemid 39060927)
137. Seidemann K., Zimmermann M., Book M., Meyer U., Burkhardt B., Welte K., Reiter A., Stanulla M., Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95. Journal of Clinical Oncology 2005 23 33 8414 8421 2-s2.0-33644667528 10.1200/JCO.2005.01.2179
138. Lee Y. H., Ji J. D., Song G. G., Tumor necrosis factor- α promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. Journal of Rheumatology 2007 34 1 43 49 2-s2.0-33846239452 (Pubitemid 46106561)
139. Mamyrova G., O'Hanlon T. P., Sillers L., Malley K., James-Newton L., Parks C. G., Cooper G. S., Pandey J. P., Miller F. W., Rider L. G., Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis and Rheumatism 2008 58 12 3941 3950 2-s2.0-57349185973 10.1002/art.24039
140. Chinoy H., Salway F., John S., Fertig N., Tait B. D., Oddis C. V., Ollier W. E. R., Cooper R. G., Tumour necrosis factor- α single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 2007 46 9 1411 1416 2-s2.0-34548242316 10.1093/rheumatology/kem145 (Pubitemid 47317085)
141. Ferguson L. R., Han D. Y., Huebner C., Petermann I., Barclay M. L., Gearry R. B., McCulloch A., Demmers P. S., Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand caucasian population. Gastroenterology Research and Practice 2009 2009 9 2-s2.0-76349112458 10.1155/2009/591704 591704
142. Skora J., Šubrt I., Dědek P., Siala K., Schwarz J., MacHalová V., Varvaovská J., Pazdiora P., Pozler O., Stožick F., Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G→A and pediatric inflammatory bowel disease: implications in ulcerative colitis and crohn's disease. Journal of Pediatric Gastroenterology and Nutrition 2006 42 5 479 487 2-s2.0-33744503655 10.1097/01.mpg.0000221917.80887.9e (Pubitemid 43804724)